<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Neuro Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">Neuro-oncology</journal-id>
        <journal-id journal-id-type="pmc-domain-id">310</journal-id>
        <journal-id journal-id-type="pmc-domain">neuroncol</journal-id>
        <journal-id journal-id-type="publisher-id">neuonc</journal-id>
        <journal-title-group>
          <journal-title>Neuro-Oncology</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1522-8517</issn>
        <issn pub-type="epub">1523-5866</issn>
        <publisher>
          <publisher-name>Oxford University Press</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC5596171</article-id>
        <article-id pub-id-type="pmcid-ver">PMC5596171.1</article-id>
        <article-id pub-id-type="pmcaid">5596171</article-id>
        <article-id pub-id-type="pmcaiid">5596171</article-id>
        <article-id pub-id-type="pmid">28472509</article-id>
        <article-id pub-id-type="doi">10.1093/neuonc/nox086</article-id>
        <article-id pub-id-type="publisher-id">nox086</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Clinical Investigations</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Thomas</surname>
              <given-names initials="AA">Alissa A</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
            <xref ref-type="author-notes" rid="fn-0002">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Abrey</surname>
              <given-names initials="LE">Lauren E</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
            <xref ref-type="author-notes" rid="fn-0002">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Terziev</surname>
              <given-names initials="R">Robert</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Raizer</surname>
              <given-names initials="J">Jeffrey</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Martinez</surname>
              <given-names initials="NL">Nina L</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
            <xref ref-type="author-notes" rid="fn-0002">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Forsyth</surname>
              <given-names initials="P">Peter</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
            <xref ref-type="author-notes" rid="fn-0002">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Paleologos</surname>
              <given-names initials="N">Nina</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
            <xref ref-type="author-notes" rid="fn-0002">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Matasar</surname>
              <given-names initials="M">Matthew</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sauter</surname>
              <given-names initials="CS">Craig S</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Moskowitz</surname>
              <given-names initials="C">Craig</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nimer</surname>
              <given-names initials="SD">Stephen D</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
            <xref ref-type="author-notes" rid="fn-0002">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>DeAngelis</surname>
              <given-names initials="LM">Lisa M</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kaley</surname>
              <given-names initials="T">Thomas</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Grimm</surname>
              <given-names initials="S">Sean</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
            <xref ref-type="author-notes" rid="fn-0002">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Louis</surname>
              <given-names initials="DN">David N</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Cairncross</surname>
              <given-names initials="JG">J. Gregory</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Panageas</surname>
              <given-names initials="KS">Katherine S</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Briggs</surname>
              <given-names initials="S">Samuel</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Faivre</surname>
              <given-names initials="G">Geraldine</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mohile</surname>
              <given-names initials="NA">Nimish A</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
            <xref ref-type="author-notes" rid="fn-0002">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mehta</surname>
              <given-names initials="J">Jayesh</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jonsson</surname>
              <given-names initials="P">Philip</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chakravarty</surname>
              <given-names initials="D">Debyani</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Gao</surname>
              <given-names initials="J">Jianjiong</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Brennan</surname>
              <given-names initials="CW">Cameron W</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Huse</surname>
              <given-names initials="JT">Jason T</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <name name-style="western">
              <surname>Omuro</surname>
              <given-names initials="A">Antonio</given-names>
            </name>
            <xref ref-type="aff" rid="AF0001">1</xref>
            <xref ref-type="author-notes" rid="fn-0002">*</xref>
            <xref ref-type="corresp" rid="c1"/>
          </contrib>
        </contrib-group>
        <aff id="AF0001">
<label>1</label>
<institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line>New York</addr-line>, <addr-line>New York,</addr-line><country>USA</country> (A.A.T., L.E.A., R.T., M.M., C.S.S., C.M., S.D.N., L.M.D., T.K., K.S.P., S.B., G.F., N.A.M., P.J., D.C., J.G., N.S., C.W.B., A.O.); <institution>Northwestern Memorial Hospital</institution>, <addr-line>Chicago, Illinois</addr-line>, <country>USA</country> (J.R., S.G., J.M.); <institution>NorthShore University</institution>, Evanston<addr-line>, Illinois,</addr-line><country>USA</country> (N.L.M., N.P.); <institution>University of Calgary</institution>, <addr-line>Calgary, Alberta</addr-line>, <country>Canada</country> (P.F., J.G.C.); <institution>Massachusetts General Hospital</institution>, Boston, <institution>Massachusetts</institution>, <country>USA</country>; <institution>MD Anderson Cancer Center</institution>, <addr-line>Houston, Texas</addr-line>, <country>USA</country> (D.N.L.)</aff>
        <author-notes>
          <corresp id="c1"><bold>Corresponding Author:</bold> Antonio Omuro, MD. Department of Neurology, Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, 1120 NW 14th Street, 1321, Miami, FL 33136 (<email>AOmuro@med.miami.edu</email>).</corresp>
          <fn id="fn-0002">
            <p>
<bold>*Current Address:</bold> A.A.T.: University of Vermont, Vermont; L.E.A.: Roche, Basel, Switzerland; P.F.: Moffitt Cancer Center, Florida; N.P.: Rush University Medical Center, Illinois; S.D.N.: University of Miami, Florida; N.A.M.: University of Rochester, New York; A.O.: University of Miami, Florida</p>
          </fn>
        </author-notes>
        <pub-date pub-type="ppub">
          <month>10</month>
          <year>2017</year>
        </pub-date>
        <pub-date pub-type="epub" iso-8601-date="2017-05-02">
          <day>02</day>
          <month>5</month>
          <year>2017</year>
        </pub-date>
        <volume>19</volume>
        <issue>10</issue>
        <issue-id pub-id-type="pmc-issue-id">298302</issue-id>
        <fpage>1380</fpage>
        <lpage>1390</lpage>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>10</month>
              <year>2018</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>10</month>
              <year>2018</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-07-17 05:25:17.000">
              <day>17</day>
              <month>07</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com</copyright-statement>
          <copyright-year>2017</copyright-year>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nox086.pdf"/>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nox086.pdf"/>
        <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="companion" xml:lang="en" xlink:title="editorial" journal-id="Neuro Oncol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC5596173">
          <article-title>Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role?</article-title>
          <volume>19</volume>
          <issue>10</issue>
          <date>
            <day>6</day>
            <month>9</month>
            <year>2017</year>
          </date>
          <fpage>1292</fpage>
          <lpage>1293</lpage>
          <source>Neuro-Oncology</source>
          <pub-id pub-id-type="pmcid">PMC5596173</pub-id>
          <pub-id pub-id-type="pmid">28922863</pub-id>
        </related-article>
        <abstract>
          <title>Abstract</title>
          <sec>
            <title>Background</title>
            <p>Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. </p>
          </sec>
          <sec>
            <title>Methods</title>
            <p>Patients with AO/AOA received 6 cycles of TMZ (200 mg/m<sup>2</sup> × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m<sup>2</sup>/day × 3 days, then busulfan 3.2 mg/kg/day × 3 days), followed by ASCT. Genomic characterization was performed using next-generation sequencing. </p>
          </sec>
          <sec>
            <title>Results</title>
            <p>Forty-one patients were enrolled; 85% had 1p/19q codeleted tumors. After induction, 26 patients were eligible for HDC-ASCT and 21 agreed to proceed. There were no unexpected adverse events or toxic deaths. After median follow-up of 66 months, 2-year progression-free survival (PFS) for transplanted patients was 86%, 5-year PFS 60%, and no patient has died. Among all 1p/19q codeleted patients (<italic toggle="yes">N =</italic> 33), 5-year PFS was 50% and 5-year overall survival (OS) 93%, with median time to radiotherapy not reached. Next-generation sequencing disclosed typical oligodendroglioma-related mutations, including <italic toggle="yes">IDH1</italic>, <italic toggle="yes">TERT</italic>, <italic toggle="yes">CIC</italic>, and <italic toggle="yes">FUBP1</italic> mutations in 1p/19q codeleted patients, and glioblastoma-like signatures in 1p/19q intact patients. Aside from <italic toggle="yes">IDH1</italic>, potentially oncogenic/actionable mutations were variable, depicting wide molecular heterogeneity within oligodendroglial tumors.</p>
          </sec>
          <sec>
            <title>Conclusions</title>
            <p>TMZ followed by HDC-ASCT can be safely administered to patients with newly diagnosed 1p/19q codeleted AO. This strategy was associated with promising PFS and OS, suggesting that a chemotherapy-based approach may delay the need for radiotherapy and radiation-related toxicities. Raw data for further genomic and meta-analyses are publicly available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://cbioportal.org/study?id=odg_msk_2017">http://cbioportal.org/study?id=odg_msk_2017</uri>, accessed 6 January 2017.</p>
          </sec>
          <sec>
            <title>Clinicaltrials.gov registry</title>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00588523">NCT00588523</ext-link>
            </p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>1p/19q codeletion</kwd>
          <kwd>anaplastic oligodendroglioma</kwd>
          <kwd>autologous stem cell transplant</kwd>
          <kwd>temozolomide</kwd>
        </kwd-group>
        <counts>
          <page-count count="11"/>
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
